An open-label, randomized, Phase III Study of Nivolumab in Combination
   with Ipilimumab or with Standard Chemotherapy versus Standard
   Chemotherapy in Patients with previously untreated inoperable or
   metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO
   First-line Therapy for untreated, non-resectable or metastatic
   Urothelial Carcinoma

Title:: An open-label, randomized, Phase III Study of Nivolumab in Combination with Ipilimumab or with Standard Chemotherapy versus Standard Chemotherapy in Patients with previously untreated inoperable or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO First-line Therapy for untreated, non-resectable or metastatic Urothelial Carcinoma
Document type:: Editorial Material
Author(s):: Rexer, H.; Retz, M.; Waller, C.
Journal title abbreviation:: Urologe A
Year:: 2018
Journal volume:: 57
Journal issue:: 7
Pages contribution:: 880-881
Fulltext / DOI:: doi:10.1007/s00120-018-0698-z
Print-ISSN:: 0340-2592
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: